Market Overview

Alkermes Announces Advances in Late-Stage CNS Pipeline

Alkermes
(NASDAQ: ALKS) today announced new developments related to its
late-stage product candidates in its proprietary central nervous system
(CNS) pipeline. The company unveiled aripiprazole lauroxil two-month, a
new product candidate addition to its portfolio of atypical
antipsychotics for the treatment of schizophrenia. If approved,
aripiprazole lauroxil two-month would be the first and only long-acting
atypical antipsychotic medication dosed every two months. This new
two-month product candidate is designed to provide physicians and
patients with an even longer dosing option than the once-monthly
formulation of aripiprazole lauroxil, which is currently completing the
phase 3 study, with topline results expected in the first half of 2014.
In addition, Alkermes provided details regarding its pivotal phase 3

See full press release

Posted-In: News Guidance Contracts FDA Management Global

 

Most Popular

Related Articles (ALKS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters